What class of compound is KPV?

KPV is classified as a α-MSH-derived anti-inflammatory tripeptide. Within this class, alternative names and analogues include Lysine-Proline-Valine, α-MSH(11-13). The class-level pharmacology shapes both the clinical applications and the safety profile; the protocol / scheduling / cycling literature treats KPV alongside its class peers when evaluating relative merits.

What are the safety considerations for KPV?

Excellent tolerability. No pigmentation effects. For scheduling and cycle use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. KPV's Short (minutes) pharmacokinetic profile and subq/oral/topical administration route influence the side-effect profile in predictable ways.

What is the mechanism of action of KPV?

Suppresses NF-κB activation and IL-1β release. Stabilises mast cells. Antimicrobial against C. albicans and S. aureus. Acts on gut mucosa to reduce inflammation in IBD models. Does not engage melanocortin receptors strongly, avoiding tanning effects. For scheduling and cycle applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Suppresses NF-κB activation and IL-1β release. The protocol / scheduling / cycling interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is the standard dosing protocol for KPV?

Conventional KPV dosing is 200-500 mcg 1-2x daily subq or oral via subq/oral/topical. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How do I schedule KPV alongside my existing stack?

KPV's schedule is built around its Short (minutes) pharmacokinetics and 1-2x daily subq or oral dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

How does KPV compare to BPC-157 and TB-500?

KPV (α-MSH-derived anti-inflammatory tripeptide, Short (minutes) half-life, 200-500 mcg typical dose) differs from peers in the comparison table above. The principal points of difference relative to BPC-157 and TB-500 are mechanism, half-life, and target system. The full comparison is in the table above; specific stack selection depends on which dimension matters for the application.

Home/ Compounds/ KPV

KPV

Protocol

Scheduling KPV alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. The C-terminal tripeptide of α-melanocyte-stimulating hormone — anti-inflammatory and antimicrobial without α-MSH's pigmentation effects. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Multi-Peptide TimingLoading PhaseStack SchedulingWash-OutCycle Design

Key Takeaways

Scheduling lens: KPV's Short (minutes) half-life via subq/oral/topical places it in the multi-daily-dosing bucket.
Mechanism: Suppresses NF-κB activation and IL-1β release.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Suppresses NF-κB activation and IL-1β release. Stabilises mast cells. Antimicrobial against C. albicans and S. aureus. Acts on gut mucosa to reduce inflammation in IBD models. Does not engage melanocortin receptors strongly, avoiding tanning effects. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for KPV.

Daily and weekly timing

KPV with a Short (minutes) half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1-2x daily SubQ or oral, with consistency mattering more than the absolute clock time of any single dose.

Cycle length and off-cycle planning

Standard KPV cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Stack scheduling with other compounds

When KPV is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Oral and subcutaneous compounds can be timed independently; the routes do not interact. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Protocol / Scheduling / Cycling Applications

Cycle Design

Schedule design for KPV in cycle design starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Wash-Out

The most-asked scheduling question for KPV in wash-out is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Loading Phase

For loading phase scheduling, KPV is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Off-Time

Schedule design for KPV in off-time starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	200-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	120-500 mcg	4–6 weeks initial cycle
Protocol focus	SubQ	200-500 mcg	1-2x daily SubQ or oral
Maintenance phase	SubQ	140-500 mcg	Ongoing with periodic pauses

Dose timing for KPV is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

KPV stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

KPV + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with KPV's mechanism in protocol / scheduling / cycling protocols.
KPV + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with KPV's mechanism in protocol / scheduling / cycling protocols.
KPV + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with KPV's mechanism in protocol / scheduling / cycling protocols.
KPV + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with KPV's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + small clinical series

Excellent tolerability. No pigmentation effects.

Lens-specific safety considerations for protocol / scheduling / cycling use of KPV: Excellent tolerability. No pigmentation effects. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

KPV anti-inflammatory tripeptide

PMID 20406134

Supporting

KPV in inflammatory bowel disease models

PMID 23291319

KPV vs Related Peptides

Compound	Profile	Onset	Best For
KPV	α-MSH-derived anti-inflammatory tripeptide	Short (minutes)	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Cycle length and off-cycle period?

Standard cycle for KPV is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Daily timing for KPV?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

What should I look for in KPV sourcing and quality?

Acceptable KPV certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 342 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the evidence base for KPV?

KPV's evidence base sits at preclinical + small clinical series. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Clinical Protocol

Start a KPV Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified KPV and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 342 Da
Sequence length: 3 aa
Half-life: Short (minutes)
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + small clinical series

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for KPV unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for KPV

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised